一、题目和背景信息
| 登记号 |
CTR20254680 |
| 相关登记号 |
暂无
|
| 药物名称 |
无 |
| 药物类型 |
化学药物
|
|
临床申请受理号
|
企业选择不公示 |
| 适应症 |
MTAP 纯合缺失的晚期或转移性非小细胞肺癌 |
| 试验专业题目 |
一项在 MTAP 纯合缺失的晚期或转移性非小细胞肺癌 (NSCLC) 受试者中评价既往治疗进展后使用 BMS-986504 单药治疗的安全性和疗效的多中心、随机、开放标签、II期研究 |
| 试验通俗题目 |
BMS-986504 在 MTAP 纯合缺失的晚期或转移性非小细胞肺癌经治受试者中的研究 |
| 试验方案编号 |
CA2400009 |
方案最新版本号
|
方案修正案01 |
| 版本日期: |
2025-02-07 |
方案是否为联合用药 |
否 |
二、申请人信息
| 申请人名称 |
[["Bristol-Myers Squibb Company"],["百时美施贵宝(中国)投资有限公司"],["Bristol Myers Squibb Co."]] |
| 联系人姓名 |
杨力 |
联系人座机 |
021-23218100 |
联系人手机号 |
18138720803 |
| 联系人Email |
alex.yang@bms.com |
联系人邮政地址 |
广东省-广州市-越秀区粤海天河城办公楼41楼BMS |
联系人邮编 |
510620 |
三、临床试验信息
1、试验目的
主要目的:在MTAP 纯合缺失的晚期或转移性 NSCLC 受试者中,按剂量水平评价研究者评估的 BMS-986504 客观缓解 (OR)
2、试验设计
| 试验分类 |
安全性和有效性 |
试验分期 |
II期
|
设计类型 |
平行分组
|
| 随机化 |
随机化
|
盲法 |
开放
|
试验范围 |
国际多中心试验
|
3、受试者信息
| 年龄 |
18岁(最小年龄)至
无上限
(最大年龄) |
| 性别 |
男+女
|
| 健康受试者 |
无
|
| 入选标准 |
[["经组织学确诊为非小细胞肺癌(NSCLC),且在肿瘤组织中检测出纯合子 MTAP 缺失;同时,受试者愿意在筛选阶段提供存档样本 / 新鲜样本,以进行中心实验室 MTAP 状态确认。"],["入组时,根据《美国癌症联合委员会分期标准(第九版)》评估,受试者为晚期或转移性非小细胞肺癌,无法接受根治性治疗且在既往治疗后进展。"],["根据RECIST v1.1,至少有1个可测量病灶。"],["最近一次治疗期间或之后记录到影像学疾病进展。"],["美国东部肿瘤协作组 (ECOG) 体能状态为0-1。"],["受试者签署 ICF 时的年龄必须≥18岁。"],["能够完整吞咽片剂(不咀嚼或压碎)。"]]
|
| 排除标准 |
[["活动性脑转移或癌性脑膜炎。"],["可能改变研究药物吸收或导致无法吞咽口服药物的胃肠道疾病史或其他胃肠道状况(例如,不受控制的恶心、呕吐、吸收不良综合征)。"],["既往接受过 PRMT5 或 MAT2A 抑制剂治疗。"],["已知对研究药物和/或其任何辅料有重度超敏反应"],["符合方案规定的其他纳入 / 排除标准。"]]
|
4、试验分组
| 试验药 |
| 序号 |
名称 |
用法 |
[["中文通用名:无 英文通用名:BMS-986504 商品名称:无","剂型:片剂 规格:200mg/片 用法用量:在采集2小时PK样本的当天(即C1D1、C1D8、C1D15和C2D1)空腹服药,在所有其他日期空腹服药或与低脂餐同服,首选早晨给药。每日一次,单次剂量400mg(21天治疗周期中每日给药,无停药期) 用药时程:连续给药直至疾病进展或发生不可接受的毒性。"],["中文通用名:无 英文通用名:BMS-986504 商品名称:无","剂型:片剂 规格:200mg/片 用法用量:在采集2小时PK样本的当天(即C1D1、C1D8、C1D15和C2D1)空腹服药,在所有其他日期空腹服药或与低脂餐同服,首选早晨给药。每日一次,单次剂量600mg(21天治疗周期中每日给药,无停药期)。 用药时程:连续给药直至疾病进展或发生不可接受的毒性。"]]
|
| 对照药 |
|
5、终点指标
| 主要终点指标及评价时间 |
| 序号 |
指标 |
评价时间 |
终点指标选择 |
[["在 MTAP 纯合缺失的晚期或转移性 NSCLC 受试者中,按剂量水平评价研究者评估的 BMS-986504 客观缓解 (OR)","各剂量水平下研究者根据实体瘤疗效评价标准 (RECIST) v1.1评估达到 OR(确认 CR 或 PR)","有效性指标"]]
|
| 次要终点指标及评价时间 |
| 序号 |
指标 |
评价时间 |
终点指标选择 |
[["在 MTAP 纯合缺失的晚期或转移性 NSCLC 受试者中,按剂量水平评价研究者评估的 BMS-986504 疾病控制 (DC) 情况","各剂量水平下研究者根据RECIST v1.1评估达到 DC(BOR 为确认 CR、确认 PR 或 SD)","有效性指标"],["在 MTAP 纯合缺失的晚期或转移性 NSCLC 受试者中,按剂量水平评价研究者评估的 BMS-986504 临床获益 (CB)","各剂量水平下研究者根据RECIST v1.1评估达到 CB(BOR 为确认 CR、确认 PR 或 治疗开始后至少6个月的SD)","有效性指标"],["在 MTAP 纯合缺失的晚期或转移性 NSCLC 受试者中,按剂量水平评价研究者评估的 BMS-986504 缓解持续时间 (DOR)","各剂量水平下研究者根据RECIST v1.1评估的 DOR,定义为从首次记录客观肿瘤缓解(CR 或 PR)至疾病进展或全因死亡(以先发生者为准)日期的时间","有效性指标"],["在 MTAP 纯合缺失的晚期或转移性 NSCLC 受试者中,按剂量水平评价研究者评估的 BMS-986504 无进展生存期 (PFS)","各剂量水平下研究者根据RECIST v1.1评估的 PFS,定义为从随机化至疾病进展或全因死亡(以先发生者为准)日期的时间","有效性指标"],["在 MTAP 纯合缺失的晚期或转移性 NSCLC 受试者中,按剂量水平评价研究者评估的 BMS-986504 至客观缓解时间 (TTOR)","各剂量水平下研究者根据RECIST v1.1评估的 TTOR,定义为从随机化至首次记录客观肿瘤缓解(CR 或 PR)日期的时间","有效性指标"],["在 MTAP 纯合缺失的晚期或转移性 NSCLC 受试者中,按剂量水平评价 BMS-986504 的安全性和耐受性","各剂量水平下治疗相关和全因 AE、SAE 和导致暂停给药、剂量降低和治疗终止的 AE 以及致死性 AE 的发生率","安全性指标"]]
|
四、研究者信息
1、主要研究者信息
| 1 |
姓名 |
邢力刚 |
学位 |
医学博士 |
职称 |
主任医师 |
| 电话 |
0531-67626819 |
Email |
xinglg@medmail.com.cn |
邮政地址 |
山东省-济南市-槐荫区济兖路440号 |
| 邮编 |
250117 |
单位名称 |
山东第一医科大学附属肿瘤医院 |
2、各参加机构信息
| 序号 |
机构名称 |
主要研究者 |
国家 |
省(州) |
城市 |
[["山东第一医科大学附属肿瘤医院","邢力刚","中国","山东省","济南市"],["吉林省肿瘤医院","刘海峰","中国","吉林省","长春市"],["首都医科大学附属北京胸科医院","刘喆","中国","北京市","北京市"],["南昌大学第一附属医院","孙龙华","中国","江西省","南昌市"],["浙江大学医学院附属邵逸夫医院","陈恩国","中国","浙江省","杭州市"],["浙江省台州医院","吕冬青","中国","浙江省","台州市"],["临沂市肿瘤医院","石建华","中国","山东省","临沂市"],["广西医科大学附属肿瘤医院","赵文华","中国","广西壮族自治区","南宁市"],["厦门大学附属第一医院","叶峰","中国","福建省","厦门市"],["GenesisCare - Campbelltown","Jessica Smith","澳大利亚","New South Wales","Campbelltown"],["Princess Alexandra Hospital","Wen Xu","澳大利亚","Queensland","Woolloongabba"],["Chris O'Brien Lifehouse","Steven Kao","澳大利亚","New South Wales","Camperdown"],["GenesisCare - St Andrew's","VY Broadbridge","澳大利亚","South Australia","Adelaide"],["Hopital Nord Guillaume-et-René-Laennec / CHU de Nantes","Elvire Pons-Tostivint","法国","Loire-Atlantique","Saint-Herblain"],["Hopitaux Universitaires Paris Centre-Hopital Cochin","Marie Wislez","法国","Paris","Paris"],["CHU GRENOBLE ALPES","Denis Moro-Sibilot","法国","Isère","La Tronche"],["Hopital Tenon","Jacques Cadranel","法国","NA","Paris"],["Hospices Civils de Lyon – Hopital Louis Pradel","Michael Duruisseaux","法国","Rhone","Bron"],["Centre Hospitalier Régional Universitaire de Nancy - H?pitaux de Brabois","Bertrand Mennecier","法国","Meurthe-et-Moselle","Vandoeuvre lès Nancy"],["Groupe hospitalier Paris saint Joseph","Carole Helissey-Danis","法国","ile-de-France","Paris"],["Institut Curie","nicolas girard","法国","Paris","Paris"],["Universitaetsklinikum Wuerzburg","Elisabeth Goebeler","德国","NA","Wuerzburg"],["Krankenhaus Martha-Maria Halle-D?lau","Miriam Moeller","德国","Sachsen-Anhalt","Halle"],["Universitaetsklinikum Koeln","Juergen Wolf","德国","NA","Koln"],["Klinikum der Ludwig-Maximilians-Universitaet Muenchen","Diego Kauffmann-Guerrero","德国","Bayern","München"],["Universitatsklinikum Frankfurt Goethe-Universitat","Fabian Acker","德国","Hessen","Frankfurt"],["Fondazione IRCCS Istituto Nazionale dei Tumori","Claudia Proto","意大利","NA","Milan"],["Istituto Nazionale Tumori IRCCS Fondazione Pascale","Alessandro Morabito","意大利","Campania","Napoli"],["ASST Grande Ospedale Metropolitano Niguarda","Giulio Cerea","意大利","Milano","Milan"],["Istituto Oncologico Veneto IRCCS","Giulia Pasello","意大利","Veneto","Padova"],["IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola","Francesco Gelsomino","意大利","Bologna","Bologna"],["Fondazione IRCCS San Gerardo dei Tintori","Diego Cortinovis","意大利","Lombardia","Monza"],["AOU della Campania Luigi Vanvitelli","Carminia Maria Della Corte","意大利","Campania","Napoli"],["National Cancer Center Hospital East","Hibiki Udagawa","日本","Chiba","Kashiwa"],["Kansai Medical University Hospital","Takayasu Kurata","日本","Osaka","Hirakata"],["Sendai Kousei Hospital","Shunichi Sugawara","日本","Miyagi","Sendai"],["Mazowiecki Szpital Onkologiczny","Renata Biernacka","波兰","Mazowieckie","Wieliszew"],["Szpital Specjalistyczny w Prabutach Spolka z o.o.","Anna Lowczak","波兰","NA","Prabuty"],["Institutul Oncologic Bucuresti “Prof. Dr. Alexandru Trestioreanu”","Aurelia Alexandru","罗马尼亚","Bucharest","Bucharest"],["S.C. Centrul de Oncologie Euroclinic S.R.L.","Constantin Volovat","罗马尼亚","Iasi","Iasi"],["Centrul de Oncologie “Sfantul Nectarie”","Michael Schenker","罗马尼亚","Dolj","Craiova"],["Institutul Regional de Oncologie","Dana Clement","罗马尼亚","Iasi","Iasi"],["Institutul Oncologic Cluj","Tudor Ciuleanu","罗马尼亚","NA","Cluj"],["SC Radiotherapy Center Cluj SRL","Andrei Ungureanu","罗马尼亚","Cluj","Floresti"],["Centrul de Diagnostic si Tratament Provita","Mircea Dediu","罗马尼亚","NA","Bucharest"],["Hospital Universitario 12 de Octubre","Luis Paz-Ares Rodriguez","西班牙","Madrid, Comunidad de","Madrid"],["Hospital Universitari i Politecnic La Fe","Oscar Juan Vidal","西班牙","València","València"],["Institut Català d'Oncologia - L'Hospitalet","Ernest Nadal Alforja","西班牙","Barcelona [Barcelona]","Hospitalet"],["Hospital Universitari Vall d'Hebron","Enriqueta Felip Font","西班牙","Barcelona [Barcelona]","Barcelona"],["H.R.U Málaga - Hospital General","Manuel Cobo-Dols","西班牙","Málaga","Málaga"],["Hospital Universitario La Paz","Javier de Castro Carpeno","西班牙","Madrid, Comunidad de","Madrid"],["Hospital Universitario Ramón y Cajal","Maria Eugenia Olmedo Garcia","西班牙","Madrid, Comunidad de","Madrid"],["HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO","Reyes Bernabe Caro","西班牙","Sevilla","SEVILLA"],["Karolinska Universitetssjukhuset Solna","Luigi DePetris","瑞典","Stockholms lan [SE-01]","Solna"],["Sahlgrenska Universitetssjukhuset","Andreas Hallqvist","瑞典","Vastra Gotalands lan [SE-14]","Gothenburg"],["Freeman Hospital","Alastair Greystoke","英国","Newcastle upon Tyne","Newcastle upon Tyne"],["Sarah Cannon Research Institute UK","Elisa Fontana","英国","London","London"],["Queen Elizabeth Hospital Birmingham","Gary Middleton","英国","England","Birmingham"],["Memorial Sloan Kettering Cancer Center","Kathryn Arbour","美国","NY","New York"],["Fred Hutchison Cancer Center","Lei Deng","美国","WA","Seattle"],["MEDICAL COLLEGE OF WISCONSIN","Jonathan Thompson","美国","WI","Milwaukee"],["Alaska Oncology and Hematology","Steven Liu","美国","AK","Anchorage"],["Dana-Farber Cancer Institute","Pasi Janne","美国","MA","Boston"],["Gabrail Cancer Center","Nashat Gabrail","美国","OH","Canton"],["Providence Portland Medical Center","Rachel Sanborn","美国","OR","Portland"],["Karmanos Cancer Institute","Dipesh Uprety","美国","MI","Detroit"],["Oregon Health and Science University","Jeremy Cetnar","美国","OR","Portland"],["Washington University School of Medicine","Anjali Rohatgi","美国","MO","St. Louis"]]
五、伦理委员会信息
| 序号 |
名称 |
审查结论 |
批准日期/备案日期 |
[["山东第一医科大学附属肿瘤医院伦理委员会","同意","2025-09-25"]]
六、试验状态信息
1、试验状态
进行中(尚未招募)
2、试验人数
| 目标入组人数 |
国内: 9 ;
国际: 130 ; |
| 已入组人数 |
国内: 登记人暂未填写该信息;
国际: 登记人暂未填写该信息; |
| 实际入组总人数 |
国内: 登记人暂未填写该信息;
国际: 登记人暂未填写该信息; |
3、受试者招募及试验完成日期
| 第一例受试者签署知情同意书日期 |
国内:登记人暂未填写该信息;
国际:登记人暂未填写该信息; |
| 第一例受试者入组日期 |
国内:登记人暂未填写该信息;
国际:登记人暂未填写该信息; |
|
试验完成日期
|
国内:登记人暂未填写该信息;
国际:登记人暂未填写该信息; |